Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ, D3FEAT Study Group
Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S, Maher L, Treloar C, Hajarizadeh B, Lamoury FMJ, Mowat Y, Schulz M, Marshall AD, Cunningham EB, Cock V, Ezard N, Gorton C, Hayllar J, Smith J, Whelan M, Martinello M, Applegate TL, Dore GJ, Grebely J, LiveRLife Study Group
National burden of influenza-associated hospitalizations in Cambodia, 2015 and 2016.
Ieng V, Tolosa MX, Tek B, Sar B, Sim K, Seng H, Thyl M, Dara C, Moniborin M, Stewart RJ, Bell LC, Theocharopoulos G, Chin S, Chau D, Iuliano AD, Moen A, Tsuyuoka R, Dueger EL, Sullivan SG, Ly S, Disclaimer, findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control, Prevention